Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency
Raymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth31University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAAbstract: O...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-10-01
|
| Series: | Research and Reports in Urology |
| Online Access: | http://www.dovepress.com/impact-of-mirabegron-extended-release-on-the-treatment-of-overactive-b-a14804 |
| _version_ | 1811191944287617024 |
|---|---|
| author | Lee RT Bamberger M Ellsworth P |
| author_facet | Lee RT Bamberger M Ellsworth P |
| author_sort | Lee RT |
| collection | DOAJ |
| description | Raymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth31University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAAbstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.Keywords: overactive bladder, incontinence, beta-3 agonist, mirabegron |
| first_indexed | 2024-04-11T23:45:27Z |
| format | Article |
| id | doaj.art-883eb795c20b48f6abf0727552034fc8 |
| institution | Directory Open Access Journal |
| issn | 2253-2447 |
| language | English |
| last_indexed | 2024-04-11T23:45:27Z |
| publishDate | 2013-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Research and Reports in Urology |
| spelling | doaj.art-883eb795c20b48f6abf0727552034fc82022-12-22T03:56:40ZengDove Medical PressResearch and Reports in Urology2253-24472013-10-012013default147157Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequencyLee RTBamberger MEllsworth PRaymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth31University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of Brown University, Providence, RI, USAAbstract: Overactive bladder is a highly prevalent disorder with a significant impact on quality of life. Antimuscarinic agents are commonly used, but persistence is limited due to unsatisfactory efficacy and/or tolerability. Mirabegron is the first beta-3 adrenoceptor agonist approved for the treatment of overactive bladder syndrome. This paper reviews the pharmacology, mechanism of action, efficacy, and safety of mirabegron. A PubMed search of all English articles pertaining to mirabegron was performed. An alternative to antimuscarinics, mirabegron has a unique mechanism, improves overactive bladder symptoms and quality of life, and has limited adverse effects and few contraindications.Keywords: overactive bladder, incontinence, beta-3 agonist, mirabegronhttp://www.dovepress.com/impact-of-mirabegron-extended-release-on-the-treatment-of-overactive-b-a14804 |
| spellingShingle | Lee RT Bamberger M Ellsworth P Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency Research and Reports in Urology |
| title | Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency |
| title_full | Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency |
| title_fullStr | Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency |
| title_full_unstemmed | Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency |
| title_short | Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency |
| title_sort | impact of mirabegron extended release on the treatment of overactive bladder with urge urinary incontinence urgency and frequency |
| url | http://www.dovepress.com/impact-of-mirabegron-extended-release-on-the-treatment-of-overactive-b-a14804 |
| work_keys_str_mv | AT leert impactofmirabegronextendedreleaseonthetreatmentofoveractivebladderwithurgeurinaryincontinenceurgencyandfrequency AT bambergerm impactofmirabegronextendedreleaseonthetreatmentofoveractivebladderwithurgeurinaryincontinenceurgencyandfrequency AT ellsworthp impactofmirabegronextendedreleaseonthetreatmentofoveractivebladderwithurgeurinaryincontinenceurgencyandfrequency |